TY  - JOUR

T1  - Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience

JO  - Oncology Reports

PY  - 2008/01/01

AU  - Ansari

ED  - 

DO  - DOI: 10.3892/or_00000088

PB  - Spandidos Publications

VL  - 20

IS  - 4

Y2  - 2024/12/22

ER  -